Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Sumpless Pump System: Reduce Floor Space Requirements

Sumps, which are pits or underground tanks used to collect water, have long been the traditional method of collecting wastewater, but they’re far from effective. Not only are they financially inefficient, sumps leave businesses vulnerable to worker safety risks, such as wet floors — not to mention the pungently unpleasant odor of wastewater, as well…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Sumps, which are pits or underground tanks used to collect water, have long been the traditional method of collecting wastewater, but they’re far from effective. Not only are they financially inefficient, sumps leave businesses vulnerable to worker safety risks, such as wet floors — not to mention the pungently unpleasant odor of wastewater, as well as requiring excess floor space.

Failing Sumps Lead to Wastewater Spills

Sumps should work to remove water that has accumulated in a water-collecting basin, but when they fail, the water must go somewhere—unfortunately, it’s typically funneled into our water sources. According to a U.S. News & World Report article, in 2017, an equipment failure at a Seattle plant dumped over 30 million gallons of sewage into Puget Sound. These types of spills have health, environmental, and monetary consequences. The truth is that sumps can fail and lead to wastewater spills.

How Sumpless Collection Works

DMP Corporation offers a sumpless solution, the first of its kind. Using sensors that determine when it’s time for the water to be pumped to a holding tank for treatment, the DMP system retains wastewater in a pipe that keeps the area under wet process relatively dry, thereby reducing odor and safety concerns while offering tremendous cost savings. Because waste is collected as it’s generated, the need for pits or underground tanks is eliminated. DMP’s sumpless solution also offers the option for automated waste segregation, with sensors (ph, conductivity, etc.). The trench with pipe can qualify as secondary containment too.

Sumpless Works as a Retrofit

DMP connects dual in-line pumps to manifolds, transferring the waste directly to the rinse water or spent solution tanks which are fitted with automatic control valves. Not only does this remove the need for sumps, it avoids RCRA mandated double containment. And because DMP’s sumpless collection connects easily to existing process piping headers, businesses will not incur added expenses to make the switch. And proper sizing at installation ensures long-term, hassle-free operation.

Rely on DMP for Sumpless Collection

Often ineffective and costly, sumps have been used for years in the wastewater treatment ecosystem. Offering many benefits, sumpless wastewater treatment is a new way to take on an old problem. The DMP solution pioneers this new approach at automating wastewater, saving organizations money while reducing the floor space requirement, eliminating safety hazards, and reducing fetid odors.

Read more at dmpcorp.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512